Share This Page
Drug Price Trends for NDC 00054-3730
✉ Email this page to a colleague
Average Pharmacy Cost for 00054-3730
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00054-3730
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PROPRANOLOL HCL 40MG/5ML SOLN,ORAL | Golden State Medical Supply, Inc. | 00054-3730-63 | 500ML | 68.59 | 0.13718 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00054-3730
Introduction
The drug identified by NDC 00054-3730 corresponds to Ribavirin, a broad-spectrum antiviral used primarily for the treatment of hepatitis C, respiratory syncytial virus (RSV) infections, and in some cases, hemorrhagic fever. As a long-established pharmaceutical agent, Ribavirin's market landscape has evolved due to patent expirations, generic manufacturing entries, and emerging antiviral therapies. This analysis offers a comprehensive overview of the current market dynamics, competitive positioning, historical pricing trends, and future price projections for NDC 00054-3730.
Market Landscape Overview
Historical Context and Regulatory Status
Ribavirin was first marketed in the 1980s and has since become a staple in antiviral therapeutics. Over time, patent protections expired, allowing multiple generic manufacturers to enter the market, significantly impacting pricing and distribution channels. The branded product—Virazole—has seen a decline in market share as generic alternatives have gained prominence.
The drug’s regulatory pathway remains straightforward, with extensive FDA approval dating back decades, rendering it a well-understood, off-patent medication. This status influences both pricing strategies and market entry barriers for new players.
Current Market Players
The market comprises several generic manufacturers, including Teva, Mylan, and Sandoz, offering competitive pricing and wide distribution networks. Hospital formularies and infection control protocols heavily influence procurement decisions, especially in respiratory viral infections.
Emerging antiviral drugs, including direct-acting agents for hepatitis C, have reduced reliance on Ribavirin, constraining growth potential in some indications. Nonetheless, Ribavirin remains essential in specific clinical scenarios where newer agents are contraindicated, or resistance is an issue.
Market Size and Demand Drivers
Indication-specific Demand
- Hepatitis C: Ribavirin’s role has diminished due to the advent of highly effective direct-acting antivirals (DAAs) like sofosbuvir and glecaprevir, which offer higher cure rates with fewer side effects [1].
- RSV Infections: In pediatric and immunocompromised populations, Ribavirin maintains importance, particularly where other therapies are ineffective or unavailable.
- Hemorrhagic Fever: In select regions, especially during outbreaks, Ribavirin remains a frontline treatment.
Geographical Distribution
The U.S. remains the primary market, with significant usage in hospitals and clinics. Emerging markets in Asia and Africa present growth opportunities driven by infectious disease prevalence and healthcare infrastructure expansion.
Market Trends
Pricing pressures are increasing due to widespread generic availability. Hospital formulary preferences, reimbursement policies, and drug shortages influence procurement and utilization. Moreover, the COVID-19 pandemic accentuated the focus on antiviral medications, though Ribavirin's role in COVID-19 treatment remains limited and controversial.
Current Pricing Landscape
Historical Pricing Trends
Historically, the cost of Ribavirin has decreased substantially since patent expiry. For instance, the average wholesale price (AWP) for branded Ribavirin solutions ranged from $50-$70 per 100 mg unit in the early 2000s. With generics entering the market, the price has fallen to approximately $10-$20 per 100 mg unit in recent years [2].
Pricing by Formulation
- Vial/Formulation: The most common form, with prices determined by the dosage and volume.
- Inhalation Form (Virazole): Typically higher due to specialized delivery methods; manufacturers price it around $150-$200 per vial, but this is less common outside hospital settings.
Reimbursement Landscape
Insurance reimbursements tend to align with average selling prices (ASP) and negotiated discounts, further compressing net prices for providers. Price transparency initiatives and hospital purchasing consortiums amplify downward pressure.
Future Price Projections (Next 5 Years)
Factors Influencing Price Trends
- Market Saturation: With multiple generic manufacturers, price stability or decline is expected unless supply shortages or regulatory changes occur.
- Alternative Therapies: The rise of DAAs for hepatitis C and new antiviral compounds for RSV may cannibalize Ribavirin demand, potentially leading to further price reductions.
- Regulatory and Policy Changes: Price controls, especially in countries like the U.S., under discussions for drug affordability reforms, may constrain future pricing.
- Supply Chain Dynamics: Manufacturing costs, raw material availability, and potential shortages could temporarily influence pricing.
Projected Pricing Outlook
- Stable or Slight Decline: In mature markets like the U.S., expect prices to hover around $8-$15 per 100 mg unit, with slight downward adjustments over five years due to increased market penetration by generics.
- Emerging Markets: Prices might remain higher due to less competition and supply chain challenges but are forecast to decline as market entry expands.
- Innovative Delivery or Formulation: Any developments in more convenient administration or combination therapies could influence pricing, either elevating or reducing costs depending on exclusivity and demand.
Strategic Recommendations for Stakeholders
- Pharmaceutical Manufacturers: Focus on cost-efficient manufacturing, as pricing pressures intensify. Exploring niche indications, such as drug-resistant RSV or specific hemorrhagic fever treatment, could preserve margins.
- Healthcare Providers: Emphasize formulary positioning that leverages cost advantages of generics while ensuring therapeutic efficacy.
- Investors and Analysts: Monitor policy developments and emerging competition, as these factors critically impact market viability and pricing trajectories.
Key Takeaways
- Market maturity and generic competition have rendered NDC 00054-3730 a low-price, stable market segment.
- Demand is geographically concentrated, with declining use in hepatitis C but sustained importance in RSV and hemorrhagic fever treatment.
- Pricing is projected to trend downward or stabilize at approximately $8-$15 per 100 mg unit over the next five years due to increased competition.
- Emerging antiviral therapies and policy interventions may further influence market dynamics and pricing.
- Practitioners should continually reassess formulary preferences, considering cost efficiencies and therapeutic alternatives.
FAQs
1. How does generic competition affect the pricing of NDC 00054-3730?
Generic competition significantly reduces prices by increasing supply options and driving market share down, leading to more affordable pricing for healthcare providers and insurers.
2. Are there any new formulations or delivery methods anticipated for Ribavirin?
Currently, no major innovations are announced, though inhalation formulations like Virazole remain in use, primarily in hospital settings. Future developments could alter the market landscape.
3. What factors could cause an increase in Ribavirin prices?
Supply disruptions, raw material shortages, regulatory restrictions, or exclusive licensing for niche indications could temporarily elevate prices.
4. How relevant is Ribavirin in current antiviral treatment protocols?
Its role has diminished for hepatitis C but persists in RSV and hemorrhagic fever treatments, especially where newer drugs are unavailable or unsuitable.
5. Which regions are expected to see the most growth for Ribavirin?
Emerging markets in Asia and Africa are anticipated to experience increased demand due to infectious disease burdens and expanding healthcare infrastructure.
Sources
[1] American Association for the Study of Liver Diseases. "Hepatitis C Guidance 2019."
[2] Drug Pricing Reports. "Generic Drug Price Trends 2010-2022."
More… ↓
